Category: Alzheimer s disease

Over 8,000 patients received tacrine in clinical trials before its 1993 FDA approval. What is Cognex known for? Primarily, it was the brand name for tacrine, the very first medication used to treat mild to moderate dementia of the Alzheimer's type. Despite being a pioneer in Alzheimer's treatment, its history is marked by significant side effects, which led to its discontinuation.

In clinical trials, approximately one-third of patients treated with tacrine, the active ingredient in Cognex, experienced reversible liver damage. For those interested in **what are the side effects of Cognex**, this serious issue, alongside other adverse reactions, ultimately led to the medication being withdrawn from the market.

Cognex (tacrine) was the first drug approved by the FDA for the treatment of mild-to-moderate dementia of the Alzheimer's type. This milestone drug, introduced in 1993, served as a foundational but flawed treatment, eventually withdrawn from the market due to significant safety concerns, primarily liver toxicity.

In January 2023, the U.S. Food and Drug Administration (FDA) initially rejected Eli Lilly's application for accelerated approval of its Alzheimer's drug, donanemab, citing a limited number of patients with adequate long-term data. This was not the only regulatory hurdle the treatment would face, as the European Medicines Agency (EMA) also refused authorization later due to an unfavorable risk-benefit assessment.

Affecting over 7 million Americans aged 65 and older, Alzheimer's disease is a growing crisis [1.7.4]. An emerging line of research investigates a compelling question: do antivirals prevent Alzheimer's by targeting latent viruses in the brain?

Approved by the FDA in 1993, tacrine was the first cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease [1.2.3, 1.4.4]. This article explores the question, 'What is tacrine used for?', its mechanism, and its place in medical history.

The U.S. Food and Drug Administration (FDA) approved donanemab (brand name Kisunla) in July 2024 for treating early symptomatic Alzheimer's disease. This monoclonal antibody, developed by Eli Lilly, is specifically designed to target and help clear beta-amyloid plaques from the brain. Understanding the meaning of Donanemab involves grasping its innovative mechanism and potential to slow the disease's progression.